TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05744921: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 202 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,262,912

Rescue Site Savings

+$1,508,608

Unlock Full NCT05744921 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05744921 Rescue Dossier →